NCT06285279View on ClinicalTrials.gov

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Lupus NephritisANCA-associated VasculitisMembranous Nephropathy - PLA2R InducedIgG4-Related Diseases
Interventions
DRUG

FKC288

"The autologous dual target BCMA/CD19-CAR-T cell of this study is obtained by infecting T cells with anti-BCMA/CD19-CAR lentiviral vectors.~Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion."

Trial Locations (1)

210016

RECRUITING

Jinling Hospital, Nanjing

All Listed Sponsors
lead

Nanjing University School of Medicine

OTHER